NCT04225442

Brief Summary

The investigators piloted the characterization of the human chronobiome. Now, this line of research is extended to explore physiological chronobiome modulated by sex, age and under evoked conditions.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
25mo left

Started Jan 2020

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
Jan 2020Jun 2028

Study Start

First participant enrolled

January 5, 2020

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

January 6, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 13, 2020

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 4, 2027

Expected
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 4, 2028

Last Updated

February 24, 2026

Status Verified

February 1, 2026

Enrollment Period

7 years

First QC Date

January 6, 2020

Last Update Submit

February 23, 2026

Conditions

Keywords

ChronobiomeMultiomicsMolecular networksCircadian clocksRemote sensing

Outcome Measures

Primary Outcomes (1)

  • Percent difference in the number of proteins with post-translational modifications found in blood samples from young versus old participants

    High-throughput proteomics analysis determines the number of proteins with and without post-translational modifications. This will explore what effect age has on the number of proteins with post-translational modifications.

    48 hours

Secondary Outcomes (8)

  • Percent difference in the number of proteins with post-translational modifications found in blood samples from female versus male participants

    48 hours

  • Percent difference in the number of proteins with post-translational modifications found in blood samples from female versus male participants and by age

    48 hours

  • Percent difference in environmental light exposure between young versus old participants

    48 hours

  • Percent difference in environmental light exposure between young versus old participants and by sex

    48 hours

  • Percent difference in physical activity between young versus old participants

    48 hours

  • +3 more secondary outcomes

Study Arms (1)

Fatty meal

OTHER

To study how a fatty meal modifies the physiological chronobiome in young and old, an isocaloric controlled liquid high fat meal (ICLHFM) will be consumed within 5 min. The ICLHFM contains an equivalent to 35% of the estimated total daily energy requirements (TDE), 60% of kcal delivered from fat while 13% come from protein and 27 % from carbohydrate.

Other: Fatty meal to challenge the physiological chronobiome in healthy young and old

Interventions

The intervention consists of a fatty meal

Fatty meal

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Young: 18-30 years of age, Old: 55-75 years of age
  • Apparent healthy
  • BMI (body mass index) up to 27.4
  • Upper arm with intact skin, i.e. without areas of breached or injured skin visible, for ambulatory blood pressure (ABP) measurements,
  • Own and use a smartphone.

You may not qualify if:

  • History of severe psychiatric illness or cognitive conditions, for example (mania, schizophrenia, or mental retardation;
  • Shift work, defined as recurring work between 22:00-05:00;
  • A diagnosis of clinically significant obstructive sleep apnea;
  • Serum creatinine \> 1.5 mg/dl in men or \>1.3 mg/del in women;
  • Significant liver disease (\>3x upper limit of normal);
  • Diabetes mellitus;
  • Past diagnosis of gastroesophageal reflux disease,
  • Transmeridian travel across ≥3 time zones in the two weeks before the 48hr deep phenotype sessions;
  • Use of oral or intravenous antibiotics in the 6 months prior to enrollment;
  • Subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening;
  • \> 2 drinks of alcohol per day;
  • Use of drugs assessed in the urinary drug test;
  • Nursing or pregnant (pregnancy will be repeatedly assessed at the beginning of each of the four inpatient visits, i.e. prior to the start of blood draws);
  • Use of pacemaker or implantable Cardioverter Defibrillator (ICD);
  • Bilateral mastectomy;
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine

Philadelphia, Pennsylvania, 19104, United States

Location

Related Publications (1)

  • Skarke C, Lahens NF, Rhoades SD, Campbell A, Bittinger K, Bailey A, Hoffmann C, Olson RS, Chen L, Yang G, Price TS, Moore JH, Bushman FD, Greene CS, Grant GR, Weljie AM, FitzGerald GA. A Pilot Characterization of the Human Chronobiome. Sci Rep. 2017 Dec 7;7(1):17141. doi: 10.1038/s41598-017-17362-6.

    PMID: 29215023BACKGROUND

Related Links

Study Officials

  • Garret A FitzGerald, MD

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR
  • Carsten C Skarke, MD

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ADJ Research Associate Professor

Study Record Dates

First Submitted

January 6, 2020

First Posted

January 13, 2020

Study Start

January 5, 2020

Primary Completion (Estimated)

January 4, 2027

Study Completion (Estimated)

June 4, 2028

Last Updated

February 24, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations